TARSUS PHARMACEUTICALS, INC. Investing Cash Flow
TARSUS PHARMACEUTICALS, INC. (TARS) reported Investing Cash Flow of -$20.68 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-06
- TARSUS PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $37.88M.
- TARSUS PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$58.56M.
- TARSUS PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $49.27M.
- TARSUS PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was -$4.74M, a 251.63% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for fiscal 2025 was -$42.12M.
- TARSUS PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for fiscal 2024 was -$199.19M, a 241.67% decline from fiscal 2023.
- TARSUS PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for fiscal 2023 was $140.60M.
- TARSUS PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for fiscal 2022 was -$144.63M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $37.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$20.68M 10-Q · filed 2026-08-06 | $28.59M derived: sum of 3 quarters · filed 2026-08-06 | $23.85M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$58.56M 10-Q · filed 2026-05-06 | -$9.29M derived: sum of 2 quarters · filed 2026-05-06 | -$14.03M derived: sum of 3 quarters · filed 2026-05-06 | -$65.73M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $49.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $44.53M derived: sum of 2 quarters · filed 2026-02-23 | -$7.17M derived: sum of 3 quarters · filed 2026-08-06 | -$42.12M 10-K · filed 2026-02-23 |
| 2025-09-30 | -$4.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$56.45M derived: sum of 2 quarters · filed 2026-08-06 | -$91.39M 10-Q · filed 2025-11-04 | -$150.96M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$51.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$86.65M 10-Q · filed 2026-08-06 | -$146.22M derived: sum of 3 quarters · filed 2026-08-06 | -$143.09M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$34.94M 10-Q · filed 2026-05-06 | -$94.52M derived: sum of 2 quarters · filed 2026-05-06 | -$91.39M derived: sum of 3 quarters · filed 2026-05-06 | -$131.91M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$59.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$56.45M derived: sum of 2 quarters · filed 2026-02-23 | -$96.97M derived: sum of 3 quarters · filed 2026-02-23 | -$199.19M 10-K · filed 2026-02-23 |
| 2024-09-30 | $3.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$37.40M derived: sum of 2 quarters · filed 2025-11-04 | -$139.62M 10-Q · filed 2025-11-04 | -$121.77M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | -$40.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$142.75M 10-Q · filed 2025-08-06 | -$124.90M derived: sum of 3 quarters · filed 2026-02-23 | -$77.53M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | -$102.22M 10-Q · filed 2025-05-01 | -$84.37M derived: sum of 2 quarters · filed 2026-02-23 | -$37.01M derived: sum of 3 quarters · filed 2026-02-23 | $27.09M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | $17.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $65.22M derived: sum of 2 quarters · filed 2026-02-23 | $129.31M derived: sum of 3 quarters · filed 2026-02-23 | $140.60M 10-K · filed 2026-02-23 |
| 2023-09-30 | $47.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $111.46M derived: sum of 2 quarters · filed 2024-11-13 | $122.75M 10-Q · filed 2024-11-13 | $35.53M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $64.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $75.39M 10-Q · filed 2024-08-08 | -$11.83M derived: sum of 3 quarters · filed 2025-02-25 | -$68.96M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $11.29M 10-Q · filed 2024-05-08 | -$75.92M derived: sum of 2 quarters · filed 2025-02-25 | -$133.05M derived: sum of 3 quarters · filed 2025-02-25 | -$133.17M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | -$87.22M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$144.35M derived: sum of 2 quarters · filed 2025-02-25 | -$144.47M derived: sum of 3 quarters · filed 2025-02-25 | -$144.63M 10-K · filed 2025-02-25 |
| 2022-09-30 | -$57.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$57.25M derived: sum of 2 quarters · filed 2023-11-09 | -$57.41M 10-Q · filed 2023-11-09 | -$57.68M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$122.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$283.00K 10-Q · filed 2023-08-10 | -$557.00K derived: sum of 3 quarters · filed 2023-08-10 | -$678.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$161.00K 10-Q · filed 2023-05-09 | -$435.00K derived: sum of 2 quarters · filed 2023-05-09 | -$556.00K derived: sum of 3 quarters · filed 2023-05-09 | -$572.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$274.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | -$395.00K derived: sum of 2 quarters · filed 2023-03-17 | -$411.00K derived: sum of 3 quarters · filed 2023-03-17 | -$586.00K 10-K · filed 2023-03-17 |
| 2021-09-30 | -$121.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$137.00K derived: sum of 2 quarters · filed 2022-11-09 | -$312.00K 10-Q · filed 2022-11-09 | -$262.00K derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$16.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$191.00K 10-Q · filed 2022-08-11 | -$141.00K derived: sum of 3 quarters · filed 2022-08-11 | -$276.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$175.00K 10-Q · filed 2022-05-11 | -$125.00K derived: sum of 2 quarters · filed 2022-05-11 | -$260.00K derived: sum of 3 quarters · filed 2022-05-11 | -$595.00K derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $50.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | -$85.00K derived: sum of 2 quarters · filed 2022-03-14 | -$420.00K derived: sum of 3 quarters · filed 2022-03-14 | -$456.00K 10-K · filed 2022-03-14 |
| 2020-09-30 | -$135.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$470.00K derived: sum of 2 quarters · filed 2021-11-10 | -$506.00K 10-Q · filed 2021-11-10 | -$530.00K derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | -$335.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$371.00K 10-Q · filed 2021-08-05 | -$395.00K derived: sum of 3 quarters · filed 2021-08-05 | |
| 2020-03-31 | -$36.00K 10-Q · filed 2021-05-11 | -$60.00K derived: sum of 2 quarters · filed 2021-05-11 | ||
| 2019-12-31 | -$24.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | -$175.00K 10-K · filed 2021-03-31 | ||
| 2019-09-30 | -$151.00K 10-Q · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |